{'fraction_non_alphanumeric': 0.02867383512544803, 'fraction_numerical': 0.02867383512544803, 'mean_word_length': 5.9875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The melanocortin MC1 receptor agonist BMS‐470539 inhibits leucocyte trafficking in the inflamed vasculature

Background and purpose:  Over three decades of research evaluating the biology of melanocortin (MC) hormones and synthetic peptides, activation of the MC type 1 (MC1) receptor has been identified as a viable target for the development of novel anti‐inflammatory therapeutic agents. Here, we have tested a recently described selective agonist of MC1 receptors, BMS‐470539, on leucocyte/post‐capillary venule interactions in murine microvascular beds.